313 A phase 1 evaluation of tebotelimab, a bispecific PD-1 x LAG-3 DART® molecule, in combination with margetuximab in patients with advanced HER2+ neoplasmsManish R. Patel, Susanna V. Ulahannan, Erika Hamilton et al.|Regular and Young Investigator Award Abstracts|2020Cited by 6